The 2026 MASCC/ISOO Annual Meeting is the foremost international and multi-disciplinary conference in supportive cancer care. It offers significant value for clinical oncologists and professionals working within the cancer care industry.
Rapid advances in cancer treatment have driven equally rapid progress in supportive care. Over three days, attendees will explore cutting‑edge research, engage with expert presentations, and take advantage of multiple networking opportunities.
This year’s conference will spotlight three key areas:
An exciting new abstract will present updated data related to Paxman’s neuropathy cryocompression device for the prevention of CIPN.
An exciting new abstract will present updated data related to Paxman’s Neuropathy cryocompression device for the prevention of CIPN.
Limb cryocompression for prevention of taxane-induced peripheral neuropathy: a phase II study, by Dr Rachel Wong, Singapore
Date/Time: Thursday 25th June 2026, 5:30pm – 5:45pm
Location: Room 203
Scheduled to take place during MASCC Parallel Session 6, this short talk by Dr Rachel Wong, Medical Oncology Consultant, National University Cancer Institute, Singapore, will present interim results from a single-arm Phase II study from patients receiving taxane-based chemotherapy. The data explores the safety and efficacy of a novel cryocompression device to help reduce chemotherapy-induced peripheral neuropathy in addition to information on tolerability, rates of dose reduction and other ongoing trials with the device.
In addition, Dr Wong will be joined at the podium by Dr Aishwarya Bandla PhD, Clinical Innovation Manager, who will present on the study design and objectives of a Phase III, three-arm, multi-centre, randomised efficacy study initiated in 2023, supported by the National Cancer Institute in the USA. This randomised trial is expected to confirm Phase II findings from the Singapore Trial and provide extensive data from its sizeable cohort for rigorous data analysis, providing complementary evidence on the device’s efficacy, safety and clinical value in the prevention of chemotherapy‑induced peripheral neuropathy.
AN IN VITRO MODEL TO INVESTIGATE CHEMOTHERAPY DRUG-INDUCED NEUROTOXICITY AND THE CYTOPROTECTIVE EFFECTS OF COOLING (CONTROLLED HYPOTHERMIA)
Presented by Hannah Etheridge (Biomolecular Sciences Research Centre, School of Biosciences and Chemistry, Sheffield Hallam University, UK)
Date/Time: Friday 26th June 2026, 9:05am
Location: Poster stage 1
This research introduces a novel, clinically relevant laboratory model designed to better understand chemotherapy‑induced peripheral neuropathy; an area of significant unmet need in oncology care. By combining advanced neuronal modelling with robust imaging and molecular techniques, the study creates a powerful platform for exploring how commonly used chemotherapies affect peripheral nerves. Clinicians will benefit from insights into a translational approach that bridges preclinical research and real‑world symptom management, while also examining the clinical relevance of cooling strategies increasingly used in supportive care.
INTERACTIVE DASHBOARD DEVELOPMENT FOR ACTIONABLE INTERPRETATION OF THE DUTCH SCALP COOLING REGISTRY
Presented by Dr Toni Brook (Biomolecular Sciences Research Centre, School of Biosciences & Chemistry, Sheffield Hallam University, UK)
Date/Time: Friday 26th June 2026, 9:05am
Location: Poster stage 3
This work presents an innovative digital solution that transforms complex scalp cooling registry data into an accessible, clinically meaningful tool. By enabling interactive exploration of real‑world patient outcomes across treatment regimens, the dashboard supports clinicians in navigating variability in chemotherapy‑induced alopecia and scalp cooling use. Attendees will gain insight into how data-driven visualisation and analytics can enhance decision-making, optimise patient counselling, and support ongoing improvements in supportive cancer care practice.
Visit the team at Booth 8 to learn more about scalp cooling, reimbursement discussions, and improving patient access.
The event takes place from June 25–27, 2026.
View the preliminary scientific agenda
here.
Clinical Innovation Manager
Head of International Sales
Head of Brand and Marketing
